- VIM0423, a potential first-in-class oral medicine for isolated dystonia, is currently being studied in a Phase 1 clinical trial; Phase 2 planned for fourth quarter of 2025 CAMBRIDGE, Mass., May 29, ...

Sodium oxybate provided temporary relief for laryngeal dystonia patients who were alcohol-responsive. The neurologic disorder causes laryngeal muscle spasms, leading to a chronically strained voice.

Laryngeal dystonia (LD), a rare neurological disease that significantly impacts a person's ability to speak due to uncontrollable vocal cord spasms, can have a debilitating effect on a person's social ...

Sodium oxybate is the first oral treatment for laryngeal dystonia to show efficacy at providing temporary relief for debilitating symptoms that impact speaking, according to the results of a Mass Eye ...

- VIM0423, a potential first-in-class oral medicine for isolated dystonia, is currently being studied in a Phase 1 clinical trial; Phase 2 planned for fourth quarter of 2025 ...